Tuesday, March 4, 2014

The Motley Fool: Can Allergan's Growth Continue?

In the world of Big Pharma, growth is a precious commodity these days. Allergan (NYSE: AGN  ) is a noteworthy exception, though, as the company continues to see strong demand for cornerstone products like Botox an Restasis, as well as its facial aesthetics line. Allergan's pipeline is somewhat more limited than an investor might normally prefer, but the company has been active in pursuing follow-on indications for existing drugs and has had a higher than normal "hit" rate for its pipeline. Though there are frustratingly few true bargains in the pharma space today, Allergan continues to look at least as though it will remain a solid holding.

Continue here:
Can Allergan's Growth Continue?

No comments: